<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618523</url>
  </required_header>
  <id_info>
    <org_study_id>ASAQ-LA 2019 DRC</org_study_id>
    <nct_id>NCT04618523</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo</brief_title>
  <acronym>TET2020</acronym>
  <official_title>Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of the Congo: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Public Health, Democratic Republic of the Congo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kinshasa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Public Health, Democratic Republic of the Congo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite all efforts, malaria remains a public health concern, in particular in the Democratic&#xD;
      Republic of the Congo (DRC). The National Malaria Control program recommends&#xD;
      artemisinin-based combination treatments (ACTs), in particular artesunate-amodiaquine or&#xD;
      artemether-lumefrantrine for the treatment of uncomplicated malaria. Previous studies&#xD;
      indicated that ACTs are still effective, with efficacy above the required threshold of 90%.&#xD;
      It is required to assess regularly the efficacy of antimalarial drugs. I In case of&#xD;
      increasing failure rates, alternative options can be decided ontime.&#xD;
&#xD;
      The purpose of this trial is to assess efficacy and safety of artesunate-amodiaquine (ASAQ&#xD;
      Winthrop®) and artemether-lumefantrine (Coartem Dispersible®) at day 28 in the treatment of&#xD;
      uncomplicated Plasmodium falciparum malaria in six surveillance sites around DRC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IV, randomized, open label, 2-arm trial. It will be performed in six malaria&#xD;
      sentinel site around the Democratic Republic of the Congo. Children aged 6 to 59 months with&#xD;
      confirmed Plasmodium falciparum uncomplicated malaria will be enrolled after informed consent&#xD;
      granted by a parent or guardian. They will be randomized to receive either&#xD;
      artesunate-amodiaquine or artemether lumefrantrine during 3 days (directly observed&#xD;
      treatment) and then followed up until day 28. At each visit, clinical examination will be&#xD;
      done and malaria testing as well. Hemoglobin level will be measured on recruitment day and&#xD;
      then every two weeks until day 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR adjusted efficacy</measure>
    <time_frame>28 days</time_frame>
    <description>absence of fever and negative blood smear during the follow-up until day 28 and new infections occurred during the follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of adverse events and serious adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Number of adverse events and serious adverse events that every participant will experience</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with positive blood smear at day 3</measure>
    <time_frame>3 days</time_frame>
    <description>Number of participants who will still have parasites on day 3</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Presence of Plasmodium falciparum resistance markers and deletion of HRP2</measure>
    <time_frame>28 days</time_frame>
    <description>Resistance markers and deletion of HRP2 will be assessed</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1056</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Artesunate-amodiaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days for children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artemether-lumefantrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).&#xD;
One tablet twice daily for children weighing 5 to &lt;15 kg, two tablets twice daily for those weighing 15 to &lt;25 kg and three tablets twice daily for those weighing 25 to &lt; 35 kg, for three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate-amodiaquine</intervention_name>
    <description>Artemisinin-based combination treatment</description>
    <arm_group_label>Artesunate-amodiaquine</arm_group_label>
    <other_name>ASAQ Winthrop®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
    <description>Artemisinin-based combination treatment</description>
    <arm_group_label>Artemether-lumefantrine</arm_group_label>
    <other_name>Coartem dispersible®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  children aged 6 to 59 months&#xD;
&#xD;
          -  monoinfection with Plasmodium falciparum with asexual parasite count of 2,000 to&#xD;
             200,000/µL&#xD;
&#xD;
          -  axillary temperature ≥ 37.5 °C&#xD;
&#xD;
          -  ability to swallow oral medication&#xD;
&#xD;
          -  ability and willingness to comply with the protocol for the duration of the study and&#xD;
             to comply with the study visit schedule;&#xD;
&#xD;
          -  informed consent from a parent or aguardian&#xD;
&#xD;
          -  living within the study catchment area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of general danger signs in children aged under 5 years or signs of severe&#xD;
             falciparum malaria according to the definitions of WHO;&#xD;
&#xD;
          -  body weight &lt; 5kg&#xD;
&#xD;
          -  hemoglobin level &lt; 5g/ dL or hematocrit &lt; 15%&#xD;
&#xD;
          -  presence of severe malnutrition&#xD;
&#xD;
          -  presence of febrile conditions due to diseases other than malaria (e.g. measles, acute&#xD;
             lower respiratory tract infection, severe diarrhoea with dehydration) or other known&#xD;
             underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases,&#xD;
             HIV/AIDS);&#xD;
&#xD;
          -  regular medication, which may interfere with antimalarial pharmacokinetics;&#xD;
&#xD;
          -  malaria treatment within 2 days prior to recruitment&#xD;
&#xD;
          -  history of hypersensitivity reactions or contraindications to any of the medicines&#xD;
             being tested or used as alternative treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gauthier Mesia Kahunu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Kinshasa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gauthier Mesia Kahunu, PhD</last_name>
    <phone>+243841209996</phone>
    <email>mesia.kahunu@unikin.ac.cd</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Mukomena Sompwe, PhD</last_name>
    <email>mukomena3@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Santé Lupidi 1</name>
      <address>
        <city>Kapolowe</city>
        <state>Haut-Katanga</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre de Santé de Référence Mikalayi</name>
      <address>
        <city>Kazumba</city>
        <state>Kasai-central</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre Evangélique de Coopération</name>
      <address>
        <city>Kimpese</city>
        <state>Kongo Central</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre de Santé de Référence Rutshuru</name>
      <address>
        <city>Rutshuru</city>
        <state>Nord-Kivu</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre de Santé Foyer Social</name>
      <address>
        <city>Kisangani</city>
        <state>Tshopo</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre de Santé Boende 2 Nsele</name>
      <address>
        <city>Boende</city>
        <state>Tshuapa</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Mitashi Mulopo, PhD</last_name>
      <phone>+243829233811</phone>
      <email>patrick.mitashi@unikin.ac.cd</email>
    </contact>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 13, 2021</last_update_submitted>
  <last_update_submitted_qc>November 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Public Health, Democratic Republic of the Congo</investigator_affiliation>
    <investigator_full_name>Prof. Gauthier Mesia Kahunu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

